Enzyme replacement therapy in nine patients with Fabry disease;Enzymothérapie substitutive chez neuf patients atteints de la maladie de Fabry

Medecine/Sciences

Volumn 21, Issue SPEC. ISS. NOV., 2005, Pages 62-65

  Alamartine, Éric ^a  

^a HÔPITAL NORD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE BETA;

CLINICAL ARTICLE; CONFERENCE PAPER; ENZYME REPLACEMENT; FABRY DISEASE; FOLLOW UP; HEALTH SURVEY; HEART DISEASE; HUMAN; KIDNEY DISEASE; POSTOPERATIVE COMPLICATION;

EID: 29944435479     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/20052111s62     Document Type: Conference Paper

References (10)

1. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha galactosidase A replacement therapy in Fabry's disease. N Engl J Med 2001; 345: 9-16.
2. Warnock DG. Fabry disease: diagnosis and management, with emphasis on the renal manifestations. Curr Opin Nephrol Hypertens 2004; 14: 87-95.
3. Ries M, Bove Bettis KE, Choyke P, et al. Parapelvic kidney cysts: a distinguishing feature with high prevalence in Fabry disease. Kidney Int 2004; 66: 978-82.
4. Mignani R, Panichi V, Giudicissi A, et al. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study. Kidney Int 2004; 65: 1381-5.
5. Ojo A, Meier-Kriesche HU, Friedman G, et al. Excellent outcome of renal transplantation in patients with Fabry's disease. Transplantation 2000; 69: 2337-9.
6. De Schoemakere G, Chauveau D, Grünfeld JP. Enzyme replacement therapy in Anderson-Fabry's disease: beneficial clinical effect on vital organ function. Nephrol Dial Transplant 2003; 18: 33-5.
7. Wilcox WR, Banikazemi M, Guffon N, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004; 75: 65-74.
8. Young E, Milks K, Morris P, et al. Is globotriaosylceramide a useful marker in Fabry disease? Acta Paediatr 2005; 94 (suppl): 51-4.
9. Siamopoulos KC. Fabry disease: kidney involvement and enzyme replacement therapy. Kidney Int 2004; 65: 744-53.
10. Lindthorst GL, Hollak CEM, Donker-Koopman E, et al. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 2004; 66: 1589-95.